Drugs / L-arabinose
L-arabinose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00302302 | Sep → Nov 2005 | glucose metabolism disease | University of Copenhagen | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-arabinose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00302302 ↗ |
| Known as | Arabinose l-form | ChEMBL registry synonym — accepted as the source's own label CHEMBL505348 ↗ |
| Known as | FEMA NO. 3255 | ChEMBL registry synonym — accepted as the source's own label CHEMBL505348 ↗ |
| Known as | NSC-1941 | ChEMBL registry synonym — accepted as the source's own label CHEMBL505348 ↗ |
| Known as | Pectin sugar | ChEMBL registry synonym — accepted as the source's own label CHEMBL505348 ↗ |
| Known as | Pectinose | ChEMBL registry synonym — accepted as the source's own label CHEMBL505348 ↗ |
| Action | Inhibit | “CONCLUSIONS: l-Arabinose inhibits sucrase activity from Caco-2 cells; 4% l-arabinose in sucrose beverages reduces postprandial glucose, insulin, and C-peptide responses and...” PMID 21677059 ↗ Jun 2011 |
| Modality | Small molecule | — CHEMBL505348 ↗ |